Cargando…

Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study

OBJECTIVE: We aimed to identify new classes in acute respiratory distress syndrome (ARDS) using physiological and clinical variables and to explore heterogeneity in the effects of glucocorticoid therapy between classes. METHODS: Using the Medical Information Mart for Intensive Care-IV database, we i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Qingbo, Pu, Yufan, Jin, Xiaoer, Zhuang, Zhiwei, Xu, Xiaowen, Ren, Xiaoqiang, Liu, Gaoqing, Ding, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028772/
https://www.ncbi.nlm.nih.gov/pubmed/36944959
http://dx.doi.org/10.1186/s12890-023-02384-w
_version_ 1784910018205712384
author Liao, Qingbo
Pu, Yufan
Jin, Xiaoer
Zhuang, Zhiwei
Xu, Xiaowen
Ren, Xiaoqiang
Liu, Gaoqing
Ding, Qi
author_facet Liao, Qingbo
Pu, Yufan
Jin, Xiaoer
Zhuang, Zhiwei
Xu, Xiaowen
Ren, Xiaoqiang
Liu, Gaoqing
Ding, Qi
author_sort Liao, Qingbo
collection PubMed
description OBJECTIVE: We aimed to identify new classes in acute respiratory distress syndrome (ARDS) using physiological and clinical variables and to explore heterogeneity in the effects of glucocorticoid therapy between classes. METHODS: Using the Medical Information Mart for Intensive Care-IV database, we identified patients with ARDS. Potential profile analysis was used to identify classes with physiological and clinical data as delineating variables. Baseline characteristics and clinical outcomes were compared between classes. The effect of glucocorticoid treatment was explored by stratifying by class and glucocorticoid treatment. RESULTS: From 2008 to 2019, 1104 patients with ARDS were enrolled in the study. The 2-class potential analysis model had the best fit (P < 0.0001), with 78% of patients falling into class 1 and 22% into class 2. Additional classes did not improve the model fit. Patients in class 2 had higher anion gap, lactate, creatinine, and glucose levels and lower residual base, blood pressure, and bicarbonate compared with class 1. In-hospital mortality and 28-day mortality were significantly higher among patients in class 2 than those in class 1 (P < 0.001). Heterogeneity of glucocorticoid treatment was observed, stratified by class and treatment, with no significant effect in class 1 (P = 0.496), increased mortality in class 2 (P = 0.001), and a significant interaction (P = 0.0381). In class 2, 28-day survival was significantly lower with glucocorticoid treatment compared with no hormone treatment (P = 0.001). CONCLUSION: We used clinical and physiological variables to identify two classes of non-COVID-19-associated ARDS with different baseline characteristics and clinical outcomes. The response to glucocorticoid therapy varied among different classes of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02384-w.
format Online
Article
Text
id pubmed-10028772
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100287722023-03-21 Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study Liao, Qingbo Pu, Yufan Jin, Xiaoer Zhuang, Zhiwei Xu, Xiaowen Ren, Xiaoqiang Liu, Gaoqing Ding, Qi BMC Pulm Med Research OBJECTIVE: We aimed to identify new classes in acute respiratory distress syndrome (ARDS) using physiological and clinical variables and to explore heterogeneity in the effects of glucocorticoid therapy between classes. METHODS: Using the Medical Information Mart for Intensive Care-IV database, we identified patients with ARDS. Potential profile analysis was used to identify classes with physiological and clinical data as delineating variables. Baseline characteristics and clinical outcomes were compared between classes. The effect of glucocorticoid treatment was explored by stratifying by class and glucocorticoid treatment. RESULTS: From 2008 to 2019, 1104 patients with ARDS were enrolled in the study. The 2-class potential analysis model had the best fit (P < 0.0001), with 78% of patients falling into class 1 and 22% into class 2. Additional classes did not improve the model fit. Patients in class 2 had higher anion gap, lactate, creatinine, and glucose levels and lower residual base, blood pressure, and bicarbonate compared with class 1. In-hospital mortality and 28-day mortality were significantly higher among patients in class 2 than those in class 1 (P < 0.001). Heterogeneity of glucocorticoid treatment was observed, stratified by class and treatment, with no significant effect in class 1 (P = 0.496), increased mortality in class 2 (P = 0.001), and a significant interaction (P = 0.0381). In class 2, 28-day survival was significantly lower with glucocorticoid treatment compared with no hormone treatment (P = 0.001). CONCLUSION: We used clinical and physiological variables to identify two classes of non-COVID-19-associated ARDS with different baseline characteristics and clinical outcomes. The response to glucocorticoid therapy varied among different classes of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02384-w. BioMed Central 2023-03-21 /pmc/articles/PMC10028772/ /pubmed/36944959 http://dx.doi.org/10.1186/s12890-023-02384-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liao, Qingbo
Pu, Yufan
Jin, Xiaoer
Zhuang, Zhiwei
Xu, Xiaowen
Ren, Xiaoqiang
Liu, Gaoqing
Ding, Qi
Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
title Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
title_full Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
title_fullStr Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
title_full_unstemmed Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
title_short Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
title_sort physiological and clinical variables identify ards classes and therapeutic heterogeneity to glucocorticoids: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028772/
https://www.ncbi.nlm.nih.gov/pubmed/36944959
http://dx.doi.org/10.1186/s12890-023-02384-w
work_keys_str_mv AT liaoqingbo physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT puyufan physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT jinxiaoer physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT zhuangzhiwei physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT xuxiaowen physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT renxiaoqiang physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT liugaoqing physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy
AT dingqi physiologicalandclinicalvariablesidentifyardsclassesandtherapeuticheterogeneitytoglucocorticoidsaretrospectivestudy